Onco-Innovations Sprints Toward Phase 1 With Drug Manufacturing Scale-Up and AstraZeneca, GSK AI Tie-Ups

Small-cap biotech Onco-Innovations gains 79% in a month, driven by AI partnerships with AstraZeneca and GSK, scale-up of cancer compound ONC010, and Australian R&D tax credits.

The small-cap biotech’s stock has been on a tear. Shares in Onco-Innovations changed hands at €0.70 on Friday, a gain of 5.11% on the day and a whopping 79% over the past month. But the ride has been anything but smooth: annualized volatility of 133% underscores the speculative nature of the paper. The reason for the euphoria lies in a confluence of milestones — two freshly minted AI collaborations with pharmaceutical heavyweights and tangible progress on the company’s lead cancer compound.

Big Pharma bets on causal AI

Inka Health, Onco-Innovations’ wholly owned subsidiary, has signed two research agreements within days of each other. The first, concluded in May 2026, is a partnership with AstraZeneca under the PROmAI programme. The goal is to use multimodal AI models that splice together molecular, clinical and imaging data to better predict oncology outcomes. The second deal, with GlaxoSmithKline, aims to make clinical trial results more transferable to real-world patient populations. Inka Health’s SynoGraph system will ingest real-world oncology data from the US via OneMedNet’s iRWD platform, which runs on Palantir Foundry, and generate forecasts on efficacy and safety of potential cancer treatments.

Dalton Pharma lifts production to kilogram scale

On the drug side, the focus is ONC010, a nanoparticle-micelle formulation of the active small molecule A83B4C63. Dalton Pharma Services, the contract manufacturer, has now scaled up production at its FDA-registered and Health Canada-licensed facility in Toronto. The company is expanding the precursor A83 to roughly 1,560 grams and performing a non-GMP synthesis of A83B4C63 in kilogram quantities. This material will support formulation work and IND-enabling studies. Concurrently, Dalton has initiated stability testing and analytical characterisation in line with ICH guidelines. Such data will be critical when the company later submits its regulatory package.

Separately, CRO Nucro-Technics is developing LC-MS methods to measure the drug in biological samples from animal studies. These assays underpin pharmacokinetics, tissue distribution and the eventual move to GLP-compliant toxicology.

Australian tax credits and a path to the FDA

Onco-Innovations has set up an Australian subsidiary to take advantage of the country’s R&D tax incentive, which can refund up to 43.5% of eligible development spending. Contracts with Avance Clinical and RDI Partners are already in place, and submissions to ethics committees and via the TGA-CTN pathway are being prepared. The plan is to use Australia as a springboard for a first-in-human study in 2026, targeting advanced tumours with PTEN or SHP-1 deficiency.

Back in North America, Avance Clinical is coordinating a pre-IND meeting with the FDA. That discussion will cover study design, data package requirements and the route into a phase 1 trial — the point at which preclinical progress either validates or stalls the entire programme.

Nasdaq listing in the works

The company is also laying groundwork for a secondary listing on the Nasdaq. A preliminary shelf prospectus filed in Canada would, once cleared, allow the issuance of various securities over a 25-month window. Both the listing and the shelf registration are subject to regulatory approvals, but the market’s attention remains fixed on the nearer-term catalyst: the FDA meeting that will determine whether the 2026 clinical timeline holds.